Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine, 344, 783–792.

Suter, T. M., Cook-Bruns, N., & Barton, C. (2004). Cardiotoxicity associated with trastuzumab (Herceptin®) therapy in the treatment of metastatic breast cancer. Breast, 13, 173–183.

Smith, I. E. (2001). Efficacy and safety of Herceptin® in women with metastatic breast cancer: Results from pivotal clinical studies. Anticancer Drugs, 12, 3–10.

Gianni, L. (2001). Tolerability in patients receiving trastuzumab with or without chemotherapy. Annals of Oncology, 12, 63–68.

Perez, E. A., & Rodeheffer, R. (2004). Clinical cardiac tolerability of trastuzumab. Journal of Clinical Oncology, 22, 322–329.

Lee, K. F., Simon, H., Chen, H., Bates, B., Hung, M. C., & Hauser, C. (1995). Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature, 378, 394–398.

Crone, S. A., Zhao, Y. Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., Ross, J. Jr., Chien, K. R., & Lee, K. F. (2002). ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine, 8, 459–465.

Liu, F. F., Stone, J. R., Schuldt, A. J., Okoshi, K., Okoshi, M. P., Nakayama, M., Ho, K. K., Manning, W. J., Marchionni, M. A., Lorell, B. H., Morgan, J. P., & Yan, X. (2005). Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. American journal of physiology. Heart and circulatory physiology, 289, H660–H666.

Sparano, J. A., & Winer, E. P. (2001). Liposomal anthracyclines for breast cancer. Seminars in Oncology, 28, 32–40.

Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D-99 Study Group. (2002). Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94, 25–36.

Baselga, J., Climent, M. A., & Lluch, A. (2004). Results of phase II of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) in patients with Her2-positive locally advanced or metastatic breast cancer (LA/MBC). European Journal of Cancer, 2(3), 132A Suppl.

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E. Jr., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Jenkins, R. B., Brown, A. M., Dakhil, S. R., Mamounas, E. P., Lingle, W. L., Klein, P. M., Ingle, J. N., & Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England Journal of Medicine, 353, 1673–1684.

Piccart-Gebhart, M. J., Procter, J., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C. H., Steger, G., Huang, C. S., Andersson, M., Inbar, M., Lichinitser, M., Lang, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T. M., Ruschoff, J., Suto, T., Greatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M. S., Gelber, R. D. & Herceptin Adjuvant (HERA) Trial Study Team. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine, 353, 1659–1672.

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Pawlicki, M., Chan, M., Smylie, M., Liu, M., Falkson, C., Pinter, T., Fornander, T., Shiftan, T., Valero, V., Mackey, J., Tabah-Fisch, I., Buyse, M., Lindsay, M. A., Riva, A., Bee, V., Pegram, M., Press, M., & Crown, J. (2005). Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Research and Treatment, 94, S1.

Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., Turpeenniemi-Hujanen, T., Jyrkkio, S., Flander, M., Helle, L., Ingalsuo, S., Johansson, K., Jaaskelainen, A. S., Pajunen, M., Rauhala, M., Kaleva-Kerola, J., Salminen, T., Leinonen, M., Elomaa, I., & Isola, J. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. The New England Journal of Medicine, 354, 809–820.

Perez, E. A., Suman, V. J., Nancy, E., & Davidson, N. E. (2005). Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Breast Cancer Research and Treatment, 94, S2038.

Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E. Jr., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., Vogel, V. G., Seay, T. E., Rastogi, P., Mamounas, E. P., Wolmark, N., & Bryant, J. (2005). Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Journal of Clinical Oncology, 23, 7811–7819.

Ewer, M. S., Vooletich, M. T., Durand, J. B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005). Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. Journal of Clinical Oncology, 23, 7820–7826.

Chien, K. R. (2006). Herceptin and the heart—a molecular modifier of cardiac failure. The New England Journal of Medicine, 354, 789–790.

Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., Martini, C., Stefanelli, M., Valagussa, P., & Bonadonna, G. (1995). Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. Journal of Clinical Oncology, 13, 2688–2699.

Gianni, L., Vigano, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., & Bonadonna, G. (1997). Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. Journal of Clinical Oncology, 15, 1906–1915.

D’ Incalci, M., Schuller, J., Colombo, T., Zucchetti, M., & Riva, A. (1998). Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations. Seminars in Oncology, 25(Suppl. 13), 16–20.

Nabholtz, J. M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., Pienkowski, T., Zaluski, J., Pinter, T., Krzakowski, M., Vorobiof, D., Leonard, R., Kennedy, I., Azli, N., Murawsky, M., Riva, A., & Pouillart, P. (2003). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. Journal of Clinical Oncology, 21, 968–975.

Olson, R. D., & Mushlin, P. S. (1990). Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. The FASEB journal, 4, 3076–3086.

Salvatorelli, E., Menna, P., Cascegna, S., Liberi, G., Calafiore, A., Gianni, L., & Minotti, G. (2006). Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies. The Journal of Pharmacology and Experimental Therapeutics, 318, 424–433.

Minotti, G., Saponiero, A., Licata, S., Menna, A., Calafiore, A. M., Teodori, G., & Gianni, L. (2001). Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clinical Cancer Research, 7, 1511–1515.

Gianni, L., Baselga, J., Eiermann, W., Guillem Porta, V., Semiglazov, V., Lluch, A., Zambetti, M., Sabadell, D., Raab, G., Llombart Cussac, A., Bozhok, A., Martinez-Agullo, A., Greco, M., Byakhov, M., Lopez Lopez, J. J., Mansutti, M., Valagussa, P., & Bonadonna, G. (European Cooperative Trial in Operable Breast Cancer Study Group). (2005). Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research, 11, 8715–8721.

Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., Guevin, R., Howell, A., Fornander, T., Hainsworth, J., Coleman, R., Vinholes, J., Modiano, M., Pinter, T., Tang, S. C., Colwell, B., Prady, C., Provencher, L., Walde, D., Rodriguez-Lescure, A., Hugh, J., Loret, C., Rupin, M., Blitz, S., Jacobs, P., Murawsky, M., Riva, A., Vogel, C., & Breast Cancer International Research Group 001 Investigators (2005). Adjuvant docetaxel for node-positive breast cancer. The New England Journal of Medicine, 352, 2302–2313.

Nabholtz, J. M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Vogel, C., Weaver, C., Walley, B., Martin, M., Chap, L., Tomiak, E., Juhos, E., Guevin, R., Howell, A., Hainsworth, J., Fornander, T., Blitz, S., Gazel, S., Loret, C., & Riva, A. (2002). Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proceedings of the American Society of Clinical Oncology, 21, 141A.

Perotti, S., Cresta, G., Grasselli, G., Capri, G., Minotti, G., & Gianni, L. (2003). Cardiotoxic effects of anthracycline-taxane combinations. Expert Opinion on Drug Safety, 2, 59–71.

Gennari, A., Salvadori, B., Donati, S., Bengala, C., Orlandini, C., Danesi, R., Del Tacca, M., Bruzzi, P., & Conte, P. F. (1999). Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors. Journal of Clinical Oncology, 17, 3596–3602.

Pagani, O., Sessa, C., Nole, F., Crivellari, D., Lombardi, D., Thurlimann, B., Hess, D., Corner, M., Bauer, J., Martinelli, G., Graffeo, R., Zucchetti, M., D’Incalci, M., & Goldhirsch, A. (2000). Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study. Annals of Oncology, 11, 985–991.

Salvatorelli, E., Menna, P., Gianni, L., & Minotti, G. (2007). Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies. The Journal of pharmacology and experimental therapeutics, 320, 790–800.

Sessa, C., Perotti, A., Salvatorelli, E., Minotti, G., Vigano, L., Lladò, A., Capri, G., Locatelli, A., Colombini, S., Peccatori, F., Voi, M., Marsoni, S., & Gianni, L. (2004). Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. European Journal of Cancer, 40, 560–570.